Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.
Abstract: The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
Type:
Grant
Filed:
April 16, 2009
Date of Patent:
May 28, 2013
Assignee:
Almirall, S.A.
Inventors:
Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Victor Giulio Matassa
Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide.
Abstract: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.
Type:
Grant
Filed:
April 26, 2011
Date of Patent:
April 16, 2013
Assignee:
Laboratories Almirall, S.A.
Inventors:
Carlos Puig Duran, Maria Isabel Crespo Crespo, Julio Cesar Castro Palomino Laria, Silvia Gual Roig, Eloisa Navarro Romero
Abstract: In order to improve the administration of powdered pharmaceuticals, the invention proposes a storage system for powdered pharmaceuticals, in particular for use or integration in a powder inhaler, for receiving a multiplicity of doses of at least one medically active substance, with at least two storage spaces (4) which are separate from each other and are each intended to hold a multiplicity of doses of a medically active substance, and the invention also proposes an inhaler for powdered pharmaceuticals, the inhaler comprising such a pharmaceutical powder cartridge system (1) as an integral part or as an exchangeable part.
Type:
Application
Filed:
October 24, 2012
Publication date:
February 28, 2013
Applicant:
ALMIRALL, S.A.
Inventors:
ALMIRALL, S.A., Pio Orviz Proxies, Xavier Llauradó
Abstract: In order to improve the administration of powdered pharmaceuticals, the invention proposes a storage system for powdered pharmaceuticals, in particular for use or integration in a powder inhaler, for receiving a multiplicity of doses of at least one medically active substance, with at least two storage spaces (4) which are separate from each other and are each intended to hold a multiplicity of doses of a medically active substance, and the invention also proposes an inhaler for powdered pharmaceuticals, the inhaler comprising such a pharmaceutical powder cartridge system (1) as an integral part or as an exchangeable part.
Abstract: New inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) are disclosed herein, as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy.
Type:
Grant
Filed:
April 25, 2008
Date of Patent:
December 18, 2012
Assignee:
Almirall, S.A.
Inventors:
Wenceslao Lumeras Amador, Paul Robert Eastwood
Abstract: The present disclosure relates to crystalline monoapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, and pharmaceutically acceptable solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the crystalline monoapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, and to methods of treatment comprising these pharmaceutical compositions.
Abstract: The present disclosure relates to compounds of formula (I): or a pharmaceutically acceptable salt or N-oxide thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds of formula (I), and to their methods of use in therapy.
Type:
Grant
Filed:
December 21, 2007
Date of Patent:
September 4, 2012
Assignee:
Laboratorios Almirall, S.A.
Inventors:
Julio Cesar Castro Palomino Laria, Montserrat Erra Sola, Maria Estrella Lozoya Toribio, Eloisa Navarro Romero
Abstract: New inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) are disclosed herein, as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy.
Type:
Grant
Filed:
February 29, 2008
Date of Patent:
September 4, 2012
Assignee:
Almirall, S.A.
Inventors:
Bernat Vidal Juan, Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Cristina Esteve Trias
Abstract: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.
Type:
Grant
Filed:
April 26, 2011
Date of Patent:
August 14, 2012
Assignee:
Almirall, S.A.
Inventors:
Carlos Puig Duran, Maria Isabel Crespo Crespo, Julio Cesar Castro Palomino Laria, Silvia Gual Roig, Eloisa Navarro Romero
Abstract: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the ?2 adrenergic receptor.
Type:
Grant
Filed:
November 10, 2008
Date of Patent:
May 15, 2012
Assignee:
Almirall, S.A.
Inventors:
Victor Giulio Matassa, Carlos Puig Duran, Maria Prat Quiñones, Laia Sole Feu, Oriol Llera Soldevila
Abstract: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.
Type:
Application
Filed:
April 26, 2011
Publication date:
May 10, 2012
Applicant:
Laboratorios Almirall, S.A.
Inventors:
Carlos PUIG DURAN, Maria Isabel CRESPO CRESPO, Julio Cesar CASTRO PALOMINO LARIA, Silvia GUAL ROIG, Eloisa NAVARRO ROMERO
Abstract: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.
Type:
Application
Filed:
April 26, 2011
Publication date:
April 26, 2012
Applicant:
Laboratorios Almirall, S.A.
Inventors:
Carlos PUIG DURAN, Maria Isabel CRESPO CRESPO, Julio Cesar CASTRO PALOMINO LARIA, Silvia GUAL ROIG, Eloisa NAVARROROMERO NAVARRO ROMERO
Abstract: A compound which is a hydroxyquinolinone derivative of formula (I), in the form of a racemate, a steroisomer or a mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, for use in, for example, normalising the lung function of a human patient.
Abstract: The present disclosure relates to 1, 2, 4 oxadiazole derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the S1P1 receptors.
Type:
Application
Filed:
December 15, 2009
Publication date:
December 22, 2011
Applicant:
ALMIRALL S.A.
Inventors:
Victor Giulio Matassa, Nuria Aguilar Izquierdo, Marta Mir Cepeda, Marta Carrascal Riera, Silvia Fonquerna Pou, Aranzazu Cardus Figueras, Julio Cesar Castro Palomino Laria, Montserrat Erra Sola
Abstract: This present disclosure relates to a process for manufacturing 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide by reacting 2-hydroxy-2,2-dithien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R)yl ester and 3-phenoxypropyl bromide, wherein the reaction takes place in a solvent or mixtures of solvents having a boiling point from 50° C. to 210° C. and chosen from ketones and cyclic ethers.
Type:
Grant
Filed:
July 16, 2007
Date of Patent:
October 25, 2011
Assignee:
Laboratorios Almirall, S.A.
Inventors:
Nuria Busquets Baque, Francesca Pajuelo Lorenzo
Abstract: The present disclosure relates to new azabiphenylaminobenzoic acid derivatives of formula (I); as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy as inhibitors of the dehydroorotate dihydrogenase (DHODH).
Type:
Application
Filed:
August 8, 2008
Publication date:
September 1, 2011
Applicant:
ALMIRALL, S.A.
Inventors:
Julio Cesar Castro Palomino Laria, Emma Terricabras Belart, Montserrat Erra Sola, Eloisa Navarro Romero, Silvia Fonquerna Pou, Aranzazu Cardus Figueras, Maria Estrella Lozoya Toribio
Abstract: A compound of formula (I) or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof wherein R1 is a group chosen from —CH2OH and —NHC(O)H; R2 is a hydrogen atom or R1 together with R2 form the group —NH—C(O)—CH?CH—, wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R1 and the carbon atom is bound to the carbon atom in the phenyl ring holding R2; R3 is chosen from a hydrogen atom, a halogen atom and groups chosen from —SO—R5, —SO2—R5, —NH—CO—NH2, —CO—NH2, hydantoino, C1-4alkyl, C1-4alkoxy and —SO2NR5R6; R4 is chosen from a hydrogen atom, a halogen atom and a C1-4 alkyl group; R5 is chosen from a C1-4 alkyl group and a C3-8 cycloalkyl group; R6 is independently chosen from a hydrogen atom and a C1-4 alkyl group; n, p and q are independently 0, 1, 2, 3 or 4; m and s are independently 0, 1, 2 or 3; and r is 0, 1 or 2 with the provisos that at least one of m and r is not 0, the sum n+m+p+q+r+s is 7, 8, 9, 10, 11, 12 or 13, and the sum q+r+s is 2, 3, 4, 5 or 6.
Type:
Grant
Filed:
May 17, 2006
Date of Patent:
June 21, 2011
Assignee:
Almirall, S.A.
Inventors:
Carlos Puig Duran, Maria Isabel Crespo Crespo, Julio Cesar Castro Palomino Laria, Silvia Gual Roig, Eloisa Navarro Romero
Abstract: To improve administration of powdered pharmaceuticals, a pharmaceutical powder cartridge (1) for powder inhalers for holding a pharmaceutical depot for a large number of pharmaceutical powder doses is proposed, having at least one storage space (6) and an integrated metering device, said integrated metering device comprising at least one metering slide (9, 13, 14) which can be moved approximately transversely in a metering slide channel (12) at least from a filling position to an emptying position, approximately transversely with respect to the direction of flow of the pharmaceutical powder out from the at least one storage space (6), said metering slide channel (12) with the at least one metering slide (9, 13, 14) being sealed off from the environment at least in the filling position of the metering slide (9, 13, 14), and also further measures and a corresponding inhaler.
Type:
Grant
Filed:
November 9, 2005
Date of Patent:
June 7, 2011
Assignee:
Almirall, S.A.
Inventors:
Joachim Goede, Martin Herder, Karl-Heinz Lange, Meike Eilbracht